Aurobindo Pharma has completed the acquisition of certain commercial operations in Western Europe from Actavis plc. The agreement to acquire the Actavis operations was announced in January 2014. The company acquired personnel, commercial infrastructure, products, marketing authorizations and dossier licence rights in seven European countries. Actavis and Aurobindo have also entered into a long term commercial and supply arrangement.
Following receipt of clearances from competent authorities, Aurobindo now intends to combine the strength of both enterprises (including its vertically integrated platform and existing commercial infrastructure) in these markets and to identify and maximize all opportunities to improve performance.
The acquisition will make the company one of the leading Indian pharmaceutical companies in Europe. The acquisition will also enable Aurobindo to achieve critical mass in Western Europe with a top 10 position in several key markets.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
